Lasolvan

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

ambroxol (ambroxol hydrochloride)

Доступна с:

Boehringer Ingelheim Ellas A.E.

ИНН (Международная Имя):

ambroxol (ambroxol hydrochloride)

дозировка:

30mg

Фармацевтическая форма:

tablets

Тип рецепта:

OTC

Характеристики продукта

Page 1 of 6
1.
NAME OF THE MEDICINAL PRODUCT
Lasolvan
®
tablets 30 mg
Active substance: Ambroxol hydrochloride
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 tablet contains 30 mg ambroxol hydrochloride.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets for oral use
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
PRODUCT INFORMATION
Secretolytic therapy in acute and chronic bronchopulmonary diseases
associated with impaired mucus
formation and transport.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Unless otherwise prescribed, the following doses are recommended for
Lasolvan tablets 30 mg:
_Children from 6 to 12 years of age:_
The usual dose is ½ a tablet 2 - 3 times daily (equivalent to 2 - 3 x
15 mg ambroxol hydrochloride per
day).
_Adults and adolescents over 12 years of age:_
The usual dose is 1 tablet 3 times daily (equivalent to 3 x 30 mg
ambroxol hydrochloride per day) for
the first 2 - 3 days and 1 tablet twice daily (equivalent to 2 x 30 mg
ambroxol hydrochloride per day)
thereafter.
For adults and adolescents over 12 years of age, the therapeutic
effect may be enhanced by increasing
the dose to 2 tablets twice daily (equivalent to 120 mg ambroxol
hydrochloride per day).
Lasolvan tablets 30 mg can be taken with or without food and should be
swallowed whole with
sufficient amounts of liquid (e.g. water, tea or fruit juice).
There is no restriction in principle on the duration of use, although
longer-term administration requires
medical supervision. The package leaflet informs patients that
Lasolvan tablets 30 mg should not
be
taken for more than 4 - 5 days without medical advice.
Page 2 of 6
L14923
Status:
Record no.:
FUT_v3_01.03.2013
5454473611
Mucosolvan tablets 30 mg
Product information
4.3
CONTRAINDICATIONS
Lasolvan tablets 30 mg are contraindicated in patients with known
hypersensitivity to ambroxol
hydrochloride or to any of the excipients.
Lasolvan tablets 30 mg are not suitable for children under 6 years of
age on account of their strength.
Lasolvan paediatric syr